ITRS Launches Distributed Tracing to Automate Root Cause Analysis in Hybrid IT Environments
27.5.2025 14:00:00 CEST | Business Wire | Press Release
ITRS, the global leader in real-time monitoring and observability for mission-critical, highly regulated environments, announced the release of Distributed Tracing powered by OpenTelemetry (OTel). This industry-standard, open-source approach underpins powerful new capabilities within the ITRS Analytics platform, to give enterprise IT teams deep, end-to-end visibility across microservices, APIs, containers, databases, and legacy systems, without locking them into proprietary agents or limited instrumentation.
Modern enterprise IT systems, especially in financial services, payments, and trading infrastructure, rely on fast-moving, distributed applications. When transactions span dozens of distributed services across on-prem, cloud, and containerized environments, traditional monitoring fails to deliver insight. With Distributed Tracing, ITRS customers can visualize and analyze entire request lifecycles across their technology stacks. Embracing OpenTelemetry enables ITRS customers to unify telemetry across complex hybrid architectures while remaining vendor-agnostic. This results in faster RCA, fewer escalations, and more resilient digital services. ITRS is committed to OpenTelemetry integration, and this offering complements our native telemetry pipeline capability, another key aspect of any OpenTelemetry ecosystem.
Product detail
Geneos Distributed Tracing offers out-of-the-box support for OpenTelemetry and integrates seamlessly with existing monitoring agents. Key capabilities include:
- End-to-end visibility into request paths across microservices, databases, APIs, and legacy hosts
- Real-time correlation of trace data with logs, metrics, and alerts
- Smart filtering to surface latency hotspots, service-level failures, and transaction drops
- Automated dependency mapping to contextualize incidents during peak loads or regulatory audits
- A guided tour of Distributed Tracing
By aligning trace insights with Geneos’ advanced alerting and AI-powered analytics, users can proactively detect issues before they escalate and reduce the burden of manual investigation.
Strategic context
This release represents a key milestone in ITRS’ hybrid observability roadmap and further strengthens its AIOps foundation. As organizations modernize infrastructure and adopt distributed architectures, Distributed Tracing equips them to maintain control, ensure compliance, and deliver seamless digital experiences under pressure.
“Distributed architectures unlock innovation—but they also introduce complexity and risk especially for highly regulated enterprises,” said Ryan Terpstra, CEO of ITRS. “With Distributed Tracing powered by OpenTelemetry (OTel), our customers gain the end-to-end visibility they need to diagnose issues faster, improve uptime, and keep critical services running smoothly, no matter how complex their environments become.”
ITRS is the global leader in real-time monitoring and observability for mission-critical, highly regulated environments. Trusted by 90% of Tier 1 capital markets firms and thousands of enterprises worldwide, we deliver deep, actionable insights that keep complex, hybrid IT ecosystems resilient, compliant, and always-on. Our solutions span on-prem, cloud, and containerized environments—empowering IT teams to prevent outages, accelerate root cause analysis, and optimize performance where it matters most.
Whether powering low-latency trading platforms, safeguarding digital banking, or ensuring uptime for critical web services, ITRS helps the world’s most demanding organizations stay one step ahead.
For more information go to www.itrsgroup.com. Follow us on LinkedIn: https://www.linkedin.com/company/itrsgroup/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527235228/en/
Contacts
itrs@aspectusgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom